Vince is President and CEO with over 25 years of experience managing brands. He has been consulting with and developing strategies for a variety of companies on a global basis, and has worked on over 1000 assignments. His background is formerly with Schering Plough.

Prior to founding the Intasol Group, Vince worked as the Global Executive Naming Director for Interbrand. He has extensive experience in the healthcare and consumer industry with clients such as sanofi-aventis, AstraZeneca, Amersham Health, Delta Airlines, Insmed Corporation, Dupont Pharmaceutical, Merck, Becton Dickinson, GlaxoSmithKline, Bristol-Myers Squibb, Novartis, Genentech, Genzyme, Bausch & Lomb, Millennium Pharmaceutical, Procter & Gamble, Molecular Insight Pharmaceuticals, Polaroid, Sony, Hershey’s, Time Warner, Mercedes Benz, Motorola, Nitec Pharma, Pfizer, Johnson & Johnson, Altana, Ferndale, Sepracor, and Wyeth. Vince also worked at the Brand Institute as the senior vice president/eastern regional manager prior to working at Interbrand. Vince founded and established the pharmaceutical naming practice at Enterprise IG and served as its global managing director of naming, prior to starting his own company.

Vince holds undergraduate and graduate degrees in Marketing from Rutgers University and Fairleigh Dickinson University. He is currently attending The Wharton School of the University of Pennsylvania. He is a guest speaker at annual global branding conferences. Vince meets on a regular basis with FDA, EMEA and HC regulatory officials to insure a continuation of GNPs (Good Naming Practices) for pharmaceutical clients.

Joanne is Senior Vice President, Project Management and has worked with various clients managing projects involving the establishment of parameters for name creation, legal screening, market research and linguistic assessment, as well as having extensive experience in name generation and creative design.

Joanne has experience working on branding projects with such clientele as Dupont Pharmaceutical, sanofi-aventis, GlaxoSmithKline, Merck, Millennium Pharmaceutical, Amersham Health, Molecular Insight Pharmaceuticals, Pfizer, Galil Medical, AstraZeneca, Mentholatum, GeneLogic, Genzyme, Ferndale, Altana, VioQuest Pharmaceuticals, Nitec Pharma AG, Insmed Corporation and Wyeth.

Prior to joining Intasol Group LLC, Joanne was an independent nomenclature consultant. Previous to that, she was a Project Manager at Ethicon, Inc., a leading major medical device company of Johnson and Johnson. Joanne managed a portfolio consisting of over 100,000 product graphic files worldwide that encompassed development, preparation of label copy to meet all FDA regulations and legal requirements, as well as package inserts. She has over 30 years of global experience in managing the graphic design area as well as worldwide projects in the quality assurance arena. In addition, she has experience and training in the quality systems regulations and ISO 9000.

Joanne is a graduate of Fairleigh Dickinson University with a BS in Marketing. She has presented and facilitated at numerous global symposia on quality assurance.

Dr. Lewis serves as adjunct Senior Regulatory Advisor to Intasol. He is President, Lewis Regulatory Consulting, LLC with over 30 years of experience in regulatory strategies required to obtain marketing approval for drugs, biologics, orphan product designations, cGMP inspections and brand name reviews in the US, EU and Canada.

Ben was formerly the Director, Regulatory Operations, FDA. Prior positions at FDA include scientific reviewer, branch chief and inspector where he had extensive experience in IND, NDA, BLA and orphan product reviews, as well as routine inspections of pharmaceutical manufacturers. He is well-versed on proprietary name review and was a member of the FDA health professionals committee that assisted with name reviews. During his tenure at FDA he developed the current labeling regulations for package inserts, as well as the pregnancy categories currently used in official labeling for describing the teratogenic effect of drugs. He created and coined the term “class labeling” used to describe drug classes.

Dr. Lewis recently worked as the Vice President, Regulatory Affairs at Prestwick Pharmaceuticals where he provided regulatory guidance for the first orphan drug for Huntington’s disease from initial IND to advisory committee where the drug received unanimous vote of approval. He also worked at the Brand Institute as Managing Director, Regulatory Affairs, responsible for regulatory submission guidance for brand names. He has extensive experience working with clients regarding risk management strategies for proprietary names.

Ben received his pharmacy and graduate degrees in pharmaceutical sciences at Auburn University and postgraduate studies at Johns Hopkins University. In May 2002 FDA awarded him the PHS Meritorious Service Medal for helping to create and establish one of the first Master of Science degrees in Regulatory Affairs in the U.S. at San Diego State University.

As Vice President, Asia Pacific Operations, Mike has developed relationships within the Asia Pacific market assisting clients with the development and implementation of strategic business objectives and organizational structures. He is responsible for all operations for global projects in that region. Mike has extensive experience in conducting successful strategy development and research studies within the pharmaceutical industry.

In his responsibilities for the development of various pharmaceutical brand naming and key research of global brands and trademarks, Mike has worked with such clients as Merck, Wyeth, Insmed Corporation, VioQuest Pharmaceuticals, GlaxoSmithKline, and Molecular Insight Pharmaceuticals.

Mike graduated from Bloomsburg University, Bloomsburg, Pennsylvania with a BS in Marketing and is currently in an MBA program. Mike served as an officer in the 82nd Airborne.

Jeannie is the Managing Director of Professional Services. She develops professional partnerships and provides the links to doctors, pharmacists and healthcare associates with various associations.

Jeannie is responsible for preliminary research in identifying strategies and positioning within specific therapeutic categories. She has worked on projects for such clients as Merck, AstraZeneca, Molecular Insight Pharmaceuticals, Insmed Corporation, and GlaxoSmithKline.

Jeannie was an independent consultant and had responsibilities for valuation and equity of businesses for possible M&A opportunities. She holds a BS in Finance from The College of New Jersey, in Ewing, New Jersey.

Tara is the Managing Director of IntasolRx Solutions and is responsible for healthcare market research that identifies 'brand drivers' within the portfolio of service offerings. She has developed numerous market research initiatives for such companies as AstraZeneca, Merck, Molecular Insights Pharmaceuticals, GSK and Wyeth. Previous to Intasol Group Tara was a product manager for MetLife. One of her primary responsibilities included the project management of several strategic business initiatives; one of which was the Case Management Initiative. Tara was also involved in the strategy and repositioning of the Optional Life product. She has extensive experience in analyzing market and industry trends, as well as recommending growth strategies. She has developed new products and enhanced existing portfolios.

Previous to that Tara was a Project Manager/Senior Laboratory Technologist at SciLabs. She effectively managed laboratory personnel, inventory control and supply purchasing licensed in the state of NY to analyze building materials for the presence of lead and/or asbestos. She had functional authority over planning organization and project completion as well as maintained rigid time schedules/deadlines in accordance with New York City and federal safety codes.

Tara received her BS in Environmental Science with a concentration in Public Policy and Economics from the University of Massachusetts at Amherst.